Editas Medicine 관리

관리 기준 확인 2/4

Editas Medicine CEO는 Gilmore O’Neill, Jun2022 에 임명되었습니다 의 임기는 2.5 년입니다. 총 연간 보상은 $ 2.39M, 26.8% 로 구성됩니다. 26.8% 급여 및 73.2% 보너스(회사 주식 및 옵션 포함). 는 $ 133.04K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 133.04K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 4 년입니다.

주요 정보

Gilmore O’Neill

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	26.8%
CEO 임기	2.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Gilmore O’Neill 의 보수는 Editas Medicine 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$211m
Jun 30 2024	n/a	n/a	-US$193m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

보상 대 시장: Gilmore 의 총 보상 ($USD 2.39M )은 UK 시장( $USD 345.75K ).

보상과 수익: Gilmore 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gilmore O’Neill (60 yo)

2.5yrs

테뉴어

US$2,392,309

보상

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gilmore O’Neill	President	2.5yrs	US$2.39m	0.13% $ 133.0k
Erick Lucera	CFO & Executive VP	1.6yrs	US$2.69m	0.028% $ 28.0k
Linda Burkly	Executive VP & Chief Scientific Officer	1.4yrs	US$1.73m	0.018% $ 17.5k
Baisong Mei	Executive VP & Chief Medical Officer	2.4yrs	US$1.14m	0.052% $ 52.2k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.9yrs	데이터 없음	데이터 없음
George Church	Co-Founder & Scientific Advisory Board Member	11.9yrs	데이터 없음	데이터 없음
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	데이터 없음	데이터 없음
Cristi Barnett	Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Charlene Stern	Executive VP & General Counsel	no data	데이터 없음	데이터 없음
Linea Aspesi	Executive VP & Chief People Officer	1.8yrs	데이터 없음	데이터 없음
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	1.3yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: 0IFK 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gilmore O’Neill	President	no data	US$2.39m	0.13% $ 133.0k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
George Church	Co-Founder & Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Emma Reeve	Independent Chairman of the Board	3.3yrs	US$238.24k	0% $ 0
Andrew Hirsch	Independent Director	7.6yrs	US$210.56k	0.0024% $ 2.4k
Jessica Hopfield	Independent Director	6.8yrs	US$231.07k	0.082% $ 81.9k
Elliott Levy	Independent Director	1.7yrs	US$264.88k	0% $ 0
David Scadden	Independent Director	5.8yrs	US$213.06k	0% $ 0
Bernadette Connaughton	Independent Director	3.2yrs	US$215.06k	0% $ 0
Meeta Chatterjee	Independent Director	4yrs	US$205.56k	0% $ 0

4.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 0IFK 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/26 21:07
장 마감 주가	2024/12/26 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Editas Medicine, Inc. 34 애널리스트 중 17 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jack Allen	Baird
Joel Beatty	Baird
Huidong Wang	Barclays

Editas Medicine 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

President recently sold US$67k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Recent updates

Editas Medicine, Inc. to Eliminate Approximately 65% of its Workforce over the Next Six Months

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.55 loss in 3Q 2023)

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

New major risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

Independent Lead Director recently bought US$254k worth of stock

First quarter 2024 earnings released: US$0.76 loss per share (vs US$0.71 loss in 1Q 2023)

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Full year 2023 earnings released: US$2.02 loss per share (vs US$3.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.81 loss in 3Q 2022)

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.78 loss in 2Q 2022)

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Insider recently sold US$62k worth of stock

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.74 loss in 1Q 2022)

Full year 2022 earnings released: US$3.21 loss per share (vs US$2.85 loss in FY 2021)

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2021)

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.81 loss in 2Q 2021)

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.86 loss in 1Q 2021)

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold US$492k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Executive VP & Chief Medical Officer recently sold US$60k worth of stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)

Chairman recently bought US$1.2m worth of stock

Full year 2020 earnings released: US$1.98 loss per share (vs US$2.68 loss in FY 2019)

Revenue beats expectations

Editas Medicine Announces Update on Clinical Updates

Editas Medicine, Inc. Appoints James C. Mullen as President

President recently sold US$84k worth of stock

Editas Medicine, Inc. Announces Management Changes, Effective February 15, 2021

CFO, Principal Accounting Officer recently sold US$123k worth of stock

Editas Medicine, Inc. Announces Steps Down of Charles Albright as Chief Scientific Officer, Effective January 15